Redeye adjusts the short-term estimates downward due to a slightly more challenging business environment. The changes in estimates negatively affect our fair value range; however, we are still optimistic about the long-term prospects of both Ironhand and Carbonhand. We lower our Base case to SEK 16 (18) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Bioservo - Edging closer to the inflection point

© Modular Finance, source Nordic Press Releases